Market Research Logo

Global Erythropoietin Drugs Market 2017-2021

Global Erythropoietin Drugs Market 2017-2021

About Erythropoietin Drugs

The global erythropoietin drugs market is expected to witness a slow growth rate during the forecast period. In 2016, EMEA dominated the market, followed by the Americas and APAC. India and China are the leading countries in the market in APAC. While Sandoz and Dr. Reddy's Laboratories dominate the erythropoietin (EPO) drugs market in India, the market in China is led by 3SBio and Beijing SL Pharmaceutical. EMEA is also witnessing positive growth, mainly due to an increase in the manufacture of EPO biosimilars by European vendors and the use of biosimilar products in this region. However, the situation in the US is complicated due to the formation of a new legislative body to govern biosimilar products.

Technavio’s analysts forecast the global erythropoietin drugs market to grow at a CAGR of 0.79% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global erythropoietin drugs market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of branded and biosimilars used for the treatment of anemia due to renal diseases, cancer chemotherapy, antiretroviral therapy, and wounds and neural diseases.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Erythropoietin Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Amgen
  • Hoffmann-LA Roche
  • Johnson & Johnson
  • Kyowa Hakko Kirin
Other prominent vendors
  • Ahua Pharmaceutical
  • 3SBio
  • BIOSIDUS
  • Biocon
  • Boehringer Ingelheim
  • Chugai Pharmaceutical
  • Celltrion
  • Intas Pharmaceuticals
  • Cipla
  • DAICHI SANKYO
  • Dr. Reddy's Laboratories
  • Teva Pharmaceutical Industries
  • Dragon Pharma
  • Huaxin High Biotechnology
  • JCR Pharmaceuticals
  • Shanghai Kehua Bio-Engineering
  • LG Life Science
  • Novartis
  • Pfizer
  • Sandoz International
  • Shenyang Sunshine Pharmaceutical
  • Shenzhen Sai Bao Er Bio-Pharmaceutical
  • Sihuan Pharmaceutical
  • STADA
  • Uni-Bio Science
  • Wanbang Biochemical Pharmaceuticals
Market driver
  • Increase in chronic kidney disease (CKD) and dialysis patient pool.
  • For a full, detailed list, view our report
Market challenge
  • Physicians' reluctance to prescribe biosimilars.
  • For a full, detailed list, view our report
Market trend
  • Advent of biosimilars expected to improve the treatment rates.
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


  • Executive summary
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
      • Table Key buying criteria for erythropoietin drugs 2016
      • Table Impact of key customer segments on the market 2016
  • Biosimilars: Overview
    • Table Definition of biosimilars in different regions
    • Comparative analysis of biosimilars and generics
      • Table Comparison between biosimilars and generics
      • Table Factors affecting biologics and biosimilars market
      • Table Impact of biosimilars cost savings on various sectors
      • Table Factors affecting success of biosimilars
      • Table Biosimilars industry: Point-of-view
      • Table Factors influencing uptake of biosimilars
    • Biosimilars market opportunities
      • Table Global erythropoietin drugs market: Strategic factors for new biosimilar entrants
    • Challenges for new entrants
      • Table Challenges for new entrants
  • Erythropoietin: An overview
    • Table Historical timeline of EPO development
    • Clinical uses of EPO
    • Abusive uses of EPO
    • Risks of EPO use
  • Market landscape
    • Market overview
      • Table Globally approved EPO biosimilars
      • Table Overview of global erythropoietin drugs market (2016-2021)
      • Table Global erythropoietin drugs market 2016-2021 ($ billions)
      • Table Key strategies in global erythropoietin drugs market
      • Table Prospects of the global erythropoietin drugs market
      • Table Global erythropoietin drugs market snapshot: Developed and emerging markets 2016
      • Table New opportunities in global erythropoietin drugs market
      • Table Impact of factors affecting the market 2016 and 2021
      • Table Factors affecting global erythropoietin drugs market
    • Five forces analysis
      • Table Five forces analysis
  • Pipeline portfolio
    • Table Share of pipeline molecules
    • Table Pipeline share of biologics and biosimilars in global erythropoietin drugs market 2016
    • Phase III pipeline portfolio
      • Table Phase III pipeline portfolio
    • Phase II pipeline portfolio
      • Table Phase II pipeline portfolio
    • Phase I pipeline portfolio
      • Table Phase I pipeline portfolio
    • Pre-clinical pipeline portfolio
      • Table Pre-clinical pipeline portfolio
  • Marketed products portfolio
    • Table Share of biologics and biosimilars in global erythropoietin drugs market 2016
    • Table Synopsis of marketed products
  • Market segmentation by end-user
    • Hospitals
    • Retail pharmacies
      • Table Biosimilars market segmentation by end-user 2016
  • Market segmentation by application
    • End-stage renal disease
    • Cancer
    • HIV
    • Wounds and neural disease
  • Market segmentation by product
    • First-generation erythropoietin formulation
    • Second-generation erythropoietin formulation
    • Biosimilars
      • Table Global erythropoietin drugs market segmentation in by product type 2016
  • Geographical segmentation
    • Table Snapshot of global erythropoietin drugs market by geography
    • Table Erythropoietin drugs market revenue by geography 2016-2021 ($ billions)
    • Erythropoietin drugs market in EMEA
      • Table Overview of erythropoietin drugs market in EMEA (2016)
      • Table Erythropoietin drugs market in EMEA 2016-2021 ($ billions)
      • Table Share of erythropoietin drugs market in Europe 2016
    • Erythropoietin drugs market in Europe
      • Table Erythropoietin drugs market in Europe 2016-2021 ($ billions)
      • Table Europe erythropoietin drugs market: Opportunity analysis
      • Table Analysis of erythropoietin biosimilar marketed products in Europe
      • Table PEST analysis: Erythropoietin drugs market in Europe 2016
    • Erythropoietin drugs market in Americas
      • Table Overview of erythropoietin drugs market in Americas (2016)
      • Table Erythropoietin drugs market in Americas 2016-2021 ($ billions)
    • Erythropoietin drugs market in US
      • Table Erythropoietin drugs market in US 2016-2021 ($ billions)
      • Table Erythropoietin drugs market in US: Opportunity analysis
      • Table PEST analysis: Erythropoietin drugs market in US
    • Erythropoietin drugs market in APAC
      • Table Overview of erythropoietin drugs market in APAC (2016)
      • Table Erythropoietin drugs market in APAC 2016-2021 ($ billions)
      • Table Market share of erythropoietin drugs in APAC
    • Erythropoietin drugs market in China
      • Table Erythropoietin drugs market in China 2016-2021 ($ millions)
      • Table China erythropoietin drugs market: Opportunity analysis
      • Table PEST analysis: Erythropoietin drugs market in China
    • Erythropoietin drugs market in Japan
    • Market overview
      • Table Erythropoietin drugs market in Japan 2016-2021 ($ millions)
      • Table Erythropoietin drugs market in Japan 2016: Opportunity analysis
      • Table PEST analysis: Erythropoietin drugs market in Japan 2016
  • Market drivers
    • Table Impact of drivers and challenges in global erythropoietin drugs market
    • Rise in number of patent expiries
      • Table Patent analysis of biologicals in the US
      • Table Patent analysis of biologicals in Europe
    • Need for cost-effective treatment
    • Increase in CKD and dialysis patient pool
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Physicians' reluctance to prescribe biosimilars
      • Table Key reasons why physicians are reluctant to prescribe biosimilar drugs
    • Multiple manufacturing complexities
    • Development of alternative therapies
    • Complicated regulatory framework
      • Table Approval process of biologicals versus biosimilars via Public Health Service Act (PHSA) in US
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Table Impact of trends in global erythropoietin drugs market
    • Advent of biosimilars expected to improve the treatment rates
      • Table Few biosimilars currently under pipeline
    • Outsourcing of biosimilar manufacturing activities
    • High growth in the emerging markets
  • Vendor landscape
    • Competitive scenario
      • Table Competitive structure analysis of global erythropoietin drugs market 2016
      • Table Geographical presence of key vendors
      • Table Competitive scenario: Global erythropoietin drugs market vendors 2016-2021
    • Other prominent vendors
  • Key vendor analysis
    • F. Hoffmann-La Roche
      • Table F. Hoffmann La-Roche: Key highlights
      • Table F. Hoffmann La-Roche: Strength assessment
      • Table F. Hoffmann La-Roche: Strategy assessment
      • Table F. Hoffmann La-Roche: Opportunity assessment
    • Amgen
      • Table Amgen: Key highlights
      • Table Amgen: Strength assessment
      • Table Amgen: Strategy assessment
      • Table Amgen: Opportunity assessment
    • Johnson & Johnson
      • Table Johnson & Johnson: Profile
      • Table Johnson & Johnson: Strength assessment
      • Table Johnson & Johnson: Strategy assessment
      • Table Johnson & Johnson: Opportunity assessment
    • Kyowa Hakko Kirin
      • Table Kyowa Hakko Kirin: Highlights
      • Table Kyowa Hakko Kirin: Strength assessment
      • Table Kyowa Hakko Kirin: Strategy assessment
      • Table Kyowa Hakko Kirin: Opportunity assessment
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report